- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04876885
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
7 mai 2021 mis à jour par: Sarrah Lal, McMaster University
The investigators aim to study whether education, in the form of three two-minute educational videos about COVID-19 vaccine development and dissemination, reduces vaccine hesitancy and increases intent to vaccinate.
The investigators intend to use insights from this research study to develop a framework for video-based 'education prescriptions' that reduce vaccine hesitancy and increase intent to vaccinate across a number of infectious diseases.
This may have wide-ranging impact: inform practice for health promotions and public health, as well as support infectious disease related work done by healthcare professionals (e.g.
those working in travel medicine, where vaccination rates are also low).
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
The World Health Organization listed vaccine hesitancy as one of the leading threats to global health in 2019.
Vaccine hesitancy is defined as the "reluctance or refusal to vaccinate despite the availability of vaccines".
Given the novelty of the COVID-19 pandemic, hesitancy towards use of COVID-19 vaccine may be linked to the process of vaccine development and clinical trial validation of safety and/or efficacy, rather than hesitations regarding vaccines in general.
This has already inspired several education campaigns.
It is unclear whether education leads to reduced hesitance and whether reduced hesitance leads to increased intent to vaccinate.
Further, early surveys demonstrating high COVID-19 vaccine acceptance and intent to vaccinate may not reflect actual uptake, as shown by comparisons to flu vaccination uptake at a time when flu vaccines are both available, validated and largely freely accessible.
Inspiring vaccine confidence is a multifaceted challenge, and the COVID-19 pandemic has shed light on one of its aspects, specifically the public health approach to health information dissemination.
The lack of evidence-based knowledge and preparedness coupled with pandemic fatigue impacts the uptake of recommended health behaviours and puts human lives at risk.
Different people adopt different responses to health promotion materials based on a variety of socioeconomic factors.
For example, in an American study on vaccination in children, it was found that children who had never received a vaccine tended to come from affluent, college educated families, while those who had only received some recommended vaccinations came from minority families that were single parent, low-income and less likely to have completed higher education.
Almost 50% of the parents of the unvaccinated children cited concerns about vaccine safety.
The strength of beliefs leading to hesitancy may change the ability to affect intent to vaccinate.
These beliefs may be contributed to by cultural dimensions in Canada and cultures of recently immigrated individuals, with regards to individualism, collectivism, perceptions of social benefits, etc.
These factors might also impact the choice to vaccinate.
The existence of many outlets for highly varied information underscores the need for unbiased and credible education on COVID-19 vaccinations.
The investigators aim to study whether education, in the form of three two-minute educational videos about COVID-19 vaccine development and dissemination, reduces vaccine hesitancy and increases intent to vaccinate.
The investigators intend to use insights from this research study to develop a framework for video-based 'education prescriptions' that reduce vaccine hesitancy and increase intent to vaccinate across a number of infectious diseases.
This may have wide-ranging impact: inform practice for health promotions and public health, as well as support infectious disease related work done by healthcare professionals (e.g.
those working in travel medicine, where vaccination rates are also low).
Type d'étude
Interventionnel
Inscription (Anticipé)
100
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Sarrah M Lal, MBA
- Numéro de téléphone: 289.808.8597
- E-mail: lals2@mcmaster.ca
Sauvegarde des contacts de l'étude
- Nom: Faith L Maelzer, BHSc
- Numéro de téléphone: 416.576.1714
- E-mail: maelzerf@mcmaster.ca
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
16 ans et plus (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
For the general public arm:
- An understanding of the English language at a grade 8 written level
- Reside in Ontario
For the healthcare professionals and public health professionals arm:
- Licensed to practice as a healthcare professional in Ontario
- An understanding of the English language at a grade 8 written level
- Reside in Ontario
Exclusion Criteria:
- Any individuals under age 16
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: General public
The individuals recruited to the study will include those who are age 16 and older.
Due to recruitment feasibility we will focus efforts on individuals living in Ontario.
We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
|
Three two-minute educational videos about COVID-19 vaccine development and dissemination
|
|
Autre: Healthcare professionals and public health professionals
The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks.
Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers.
Public health units will disseminate surveys to their workforce.
|
Three two-minute educational videos about COVID-19 vaccine development and dissemination
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants indicating intent to vaccinate against COVID-19
Délai: One month
|
The primary end point of the study is "intent to vaccinate against COVID-19" within the general public survey.
We are looking for an increase in intent to vaccinate after the educational videos are completed.
This is a yes/no answer choice.
A change in response may be indicative of the impact of education on vaccination intent.
|
One month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in score regarding vaccine hesitation after exposure to educational materials
Délai: One month
|
The study seeks to understand whether providing video-based educational materials yields a positive change in score regarding vaccine hesitation (at least one point decrease) after exposure to educational materials.
A change in score may indicate that educational materials support a decrease in COVID-19 vaccination hesitancy in the population.
The scale title will be "Level of concern about the COVID-19 vaccine".
Values will range from 1-5, where 1 indicates no concern and 5 indicates high concern.
|
One month
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Sarrah M Lal, MBA, McMaster University
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020 Sep;26:100495. doi: 10.1016/j.eclinm.2020.100495. Epub 2020 Aug 12.
- Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol. 2020 Apr;35(4):325-330. doi: 10.1007/s10654-020-00634-3. Epub 2020 Apr 22.
- Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ; Sydney Health Literacy Lab COVID-19 group. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect Dis. 2021 Mar;21(3):318-319. doi: 10.1016/S1473-3099(20)30559-4. Epub 2020 Jun 30. No abstract available.
- Edwards B, Biddle N, Gray M, Sollis K. COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population. PLoS One. 2021 Mar 24;16(3):e0248892. doi: 10.1371/journal.pone.0248892. eCollection 2021.
- Sherman SM, Smith LE, Sim J, Amlot R, Cutts M, Dasch H, Rubin GJ, Sevdalis N. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621. doi: 10.1080/21645515.2020.1846397. Epub 2020 Nov 26.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Anticipé)
6 mai 2021
Achèvement primaire (Anticipé)
6 juin 2021
Achèvement de l'étude (Anticipé)
6 juin 2021
Dates d'inscription aux études
Première soumission
3 mai 2021
Première soumission répondant aux critères de contrôle qualité
3 mai 2021
Première publication (Réel)
7 mai 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
11 mai 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
7 mai 2021
Dernière vérification
1 mai 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 12902
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .